Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient.

TitleConsiderations for evaluating the use of intrathecal drug delivery in the oncologic patient.
Publication TypeJournal Article
Year of Publication2014
AuthorsGulati A, Puttanniah V, Hung J, Malhotra V
JournalCurr Pain Headache Rep
Date Published2014 Feb
KeywordsAnalgesics, Opioid, Evidence-Based Medicine, Female, Humans, Infusion Pumps, Implantable, Injections, Spinal, Male, Neoplasms, Pain, Intractable, Patient Selection

While the majority of cancer pain patients are successfully managed with conservative medical management, some patients may suffer from intractable pain or intolerable side effects. The implantation of an intrathecal drug delivery system offers many advantages to improve both analgesia and side effect profile. Practitioners may decide to proceed toward implantation after appropriate patient selection, and, when applicable, a suitable trial for the device. Once implantation is completed, multiple medication combinations may be used to optimize the therapeutic benefit of the device. We describe a stepwise paradigm to implement an intrathecal drug delivery program in the cancer pain population.

Alternate JournalCurr Pain Headache Rep
PubMed ID24407749